Guardant Health and Nuvalent Announce Collaboration for Cancer Therapies
Guardant Health has entered into a multi-year strategic collaboration with Nuvalent to develop companion diagnostics and support the commercialization of targeted cancer therapies through the Guardant Infinity™ platform.
PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year strategic collaboration with Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, to support the development and potential commercialization of Nuvalent’s oncology pipeline using the tissue and liquid offerings of the Guardant Infinity™ platf